http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Manufacturing of GaAs MMICs for Wireless Communications Applications
Wu-Jing Ho,Joe Liu,Hengchang Chou,Chan Shin Wu,Tsung Chi Tsai,Wei Der Chang,Frank Chou,Yu-Chi Wang 대한전자공학회 2006 Journal of semiconductor technology and science Vol.6 No.3
Two major processing technologies of GaAs HBT and pHEMT have been released in production at Win Semiconductors corp. to address the strong demands of power amplifiers and switches for both handset and WLAN communications markets. Excellent performance with low processing cost and die shrinkage features is reported from the manufactured MMICs. With the stringent tighter manufacturing quality control WIN has successfully become one of the major pure open foundry house to serve the communication industries. The advancing of both technologies to include E/D-pHEMTs and BiHEMTs likes for multifunctional integration of PA, LNA, switch and logics is also highlighted.
Manufacturing of GaAs MMICs for Wireless Communications Applications
Ho, Wu-Jing,Liu, Joe,Chou, Hengchang,Wu, Chan Shin,Tsai, Tsung Chi,Chang, Wei Der,Chou, Frank,Wang, Yu-Chi The Institute of Electronics and Information Engin 2006 Journal of semiconductor technology and science Vol.6 No.3
Two major processing technologies of GaAs HBT and pHEMT have been released in production at Win Semiconductors corp. to address the strong demands of power amplifiers and switches for both handset and WLAN communications markets. Excellent performance with low processing cost and die shrinkage features is reported from the manufactured MMICs. With the stringent tighter manufacturing quality control WIN has successfully become one of the major pure open foundry house to serve the communication industries. The advancing of both technologies to include E/D-pHEMTs and BiHEMTs likes for multifunctional integration of PA, LNA, switch and logics is also highlighted.
Kinesin-1-dependent transport of the βPIX/GIT complex in neuronal cells
( Eun-young Shin ),( Chan-soo Lee ),( Han-byeol Kim ),( Jin-hee Park ),( Kwangseok Oh ),( Gun-wu Lee ),( Eun-yul Cho ),( Hyong Kyu Kim ),( Eung-gook Kim ) 생화학분자생물학회(구 한국생화학분자생물학회) 2021 BMB Reports Vol.54 No.7
Proper targeting of the βPAK-interacting exchange factor (βPIX)/G protein-coupled receptor kinase-interacting target protein (GIT) complex into distinct cellular compartments is essential for its diverse functions including neurite extension and synaptogenesis. However, the mechanism for translocation of this complex is still unknown. In the present study, we reported that the conventional kinesin, called kinesin-1, can transport the βPIX/GIT complex. Additionally, βPIX bind to KIF5A, a neuronal isoform of kinesin-1 heavy chain, but not KIF1 and KIF3. Mapping analysis revealed that the tail of KIF5s and LZ domain of βPIX were the respective binding domains. Silencing KIF5A or the expression of a variety of mutant forms of KIF5A inhibited βPIX targeting the neurite tips in PC12 cells. Furthermore, truncated mutants of βPIX without LZ domain did not interact with KIF5A, and were unable to target the neurite tips in PC12 cells. These results defined kinesin-1 as a motor protein of βPIX, and may provide new insights into βPIX/GIT complex-dependent neuronal pathophysiology. [BMB Reports 2021; 54(7): 380-385]
Why Do Pat ients Drop Out During Radiat ion Therapy?
허승재(Seung Jae Huh),우홍균(Hong Gyun Wu),안용찬(Yong Chan Ahn),김용대(Dae Yong Kim),신경환(Kyung Hwan Shin),이규찬(Kyu Chan Lee),정원아(Won A Chong),김현주(Hyun Joo Kim) 대한방사선종양학회 1998 Radiation Oncology Journal Vol.16 No.3
목 적 : 본 연구는 계획된 방사선치료의 과정 도중에 방사선치료를 완료하지 못하는 환자들의 빈도를 조사하고 그 이유를 분석하고자 하였다. 대상 및 방법 : 삼성서울병원 치료방사선과에서 방사선치료를 받은 환자 중에서 1996년 4월부터 1997년 5월까지 방사선치료를 시행 받은 1,100명의 환자들을 대상으로 하였다. 대상 환자들 중에서 최초 계획 방사선량의 95% 이하를 받은 경우를 불완전 방사선치료로 정의하여 그 빈도와 이유를 조사하였다. 결 과 : 불완전 방사선치료의 빈도는 1,100명 중 128명으로 12%였다. 불완전 방사선치료 환자들의 운동수행능력은 전체 환자들에 비하여 불량하였으며, 방사선치료의 목적은 고식적 목적이 많았다. 불완전 방사선치료의 가장 흔한 이유는 환자의 거부였으며 이는 주로 환자의 방사선치료에 대한 불신과 경제적 부담 때문이었다. 결 론 : 불완전 방사선치료의 빈도를 줄이기 위해서는 방사선치료의 임상적 적응 여부는 물론 환자의 사회 경제적인 여건을 잘 고려하여 방사선치료의 대상 환자를 선정하는 것이 요망되며 이는 특히 고식적 방사선치료의 경우에 더욱 중요하다고 할 수 있겠다. Purpose : This study is to see how much proportion of the patients receiving radiation therapy drop out during radiation therapy and to analyze the reason for the incomplete treatment. Materials and Methods : The base population of this study was 1,100 patients with registration numbers 901th ro ugh 2,000 at Department of Radiation Oncology, Samsung Medical Center, Seoul, Korea. Authors inves-tigated the incidence of incomplete radiation therapy, which was defined as less than 95% of initially planned radiation d ose, and the reasons for incomplete radiation therapy. Results : One hundred and twenty eight patients(12%) did not complete the planned radiation therapy. The perfo rmance status of the incompletely treated patients was generally poorer than that of the base population, and the aim of radiation therapy was more commonly palliative . The most common reason for not completing the planned treatment was the patients' refusal of further radiation therapy because of the distrust of radiation therapy and/or the poor economic status . Conclusion : Careful case selection for radiation therapy with consideration of the socio economic status of the patients in addition to the clinical indication would be necessary for the reduction of incomplete treatme nt, especially in the palliative setting.
골반부 방사선 조사야 내의 소장 용적을 줄이기 위한 Small Bowel Displacement System(SBDS)의 사용
임도훈(Do Hoon Lim),허승재(Seung Jae Huh),안용찬(Yong Chan Ahn),김대용(Dae Yong Kim),우홍균(Hong Gyun Wu),김문경(Moon Kyung Kim),최동탁(Dong Rak Choi),신경환(Kyung Hwan Shin) 대한방사선종양학회 1997 Radiation Oncology Journal Vol.15 No.3
Purpose : Authors designed a customized Small Bowel Displacement System (SBDS) to displace the small bowel from the pelvic radiation fields and minimize treatment-related bowel morbidities. Methods and Materials : From August 1995 to May 1996, 55 consecutive patients who received pelvic radiation therapy with the SBDS were included in this study. The SBDS consists of a customized styrofoam compression device which can displace the small bowel from the radiation fields and an individualized immobilization abdominal board for easy daily setup in prone position. After opacifying the small bowel with Barium , the patients were laid prone and posterior-anterior (PA) and lateral (LAT) simulation films were taken with and without the SBDS. The areas of the small bowel included in the radiation fields with and without the SBDS were compared. Results : Using the SBDS, the mean small bowel area was reduced by 59% on PA and 51% on LAT films (P=0.0001). In six patients (6/55, 11%), it was possible that no small bowel was included within the treatment fields. The mean upward displacement of the most caudal small bowel was 4.8 cm using the SBDS. Only 15% (8/55) of patients treated with the SBDS manifested diarrhea requiring medication. Conclusion : The SBDS is a novel method that can be used to displace the small bowel away from the treatment portal effectively and reduce the radiation therapy morbidities. Compliance with setup is excellent when the SBDS is used. 목 적 : 저자들은 골반부 방사선 치료에 있어서 소장을 방사선 조사야 밖으로 밀어냄으로써 방사선치료로 인한 소장의 부작용을 최소화하고자 Small Bowel Displacement System (SBDS)을 만들어 환자 치료에 적용하였다. 대상 및 방법 : 1995년 8월부터 1996년 5월까지 SBDS를 이용하여 골반부에 방사선 치료를 받은 55명의 환자를 대상으로 하였다. SBDS는 환자의 하복부를 눌러줌으로써 골반부 내의 소장을 방사선 조사야 밖으로 밀어내는 Styrofoam compression device와 이로 인한 환자의 하복부 불편감을 줄이며 치료시 환자 자세의 안전성을 유지시키기 위해 환자 개개인별로 만든 Immobilization device로 구성된다. 모의치료시 소장을 조영제로 조영시킨 후 복와위 상태에서 SBDS 를 사용하기 전과 사용한 후의 후방-전방 및 측방 촬영을 하여 방사선 조사야 내에 포함되는 조영제로 조영이 되는 소장의 면적을 측정하여 서로 비교하였다. 결 과 : SBDS를 사용했을 때 사용전에 비하여 후방-전방 촬영 필름에서는 59%의 소장이 그리고 측방 촬영 필름에서는 51%의 소장이 방사선 조사야 밖으로 밀려났다(P=0.0001). 조영된 소장의 평균 상향 이동 거리는 4.8cm였으며, 55명의 환자중 단지 8명 (15%)에서만 투약이 필요할 정도의 설사를 호소하였으며, 이로 인하여 방사선치료가 중단되거나 지연된 경우는 없었다. 결 론 : SBDS는 소장을 골반부 방사선 조사야 밖으로 효과적으로 밀어내는 기구로서 방사선 치료로 인한 소장의 부작용을 감소시키는 기구이다. 또한, 제작이 용이하며 환자 치료 자세의 높은 재현성을 보였다. SBDS를 사용한 환자에서 향후 방사선 만성 부작용의 발생 빈도 감소에 기여한다면 필요한 경우에 골반부에 조사하는 방사선량을 증가시켜 보다 향상된 치료효과를 기대할 수 있겠다.
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, Seung-Oe,Li, Chia-Wei,Xia, Weiya,Cha, Jong-Ho,Chan, Li-Chuan,Wu, Yun,Chang, Shih-Shin,Lin, Wan-Chi,Hsu, Jung-Mao,Hsu, Yi-Hsin,Kim, Taewan,Chang, Wei-Chao,Hsu, Jennifer L.,Yamaguchi, Hirohito,Ding Elsevier 2016 Cancer cell Vol.30 No.6
<P><B>Summary</B></P> <P>Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization of programmed cell death-ligand 1 (PD-L1). We demonstrated that COP9 signalosome 5 (CSN5), induced by NF-κB p65, is required for TNF-α-mediated PD-L1 stabilization in cancer cells. CSN5 inhibits the ubiquitination and degradation of PD-L1. Inhibition of CSN5 by curcumin diminished cancer cell PD-L1 expression and sensitized cancer cells to anti-CTLA4 therapy.</P> <P><B>Highlights</B></P> <P> <UL> <LI> TNF-α stabilizes cancer cell PD-L1 in response to chronic inflammation </LI> <LI> Activation of NF-κB by TNF-α induces CSN5 expression leading to PD-L1 stabilization </LI> <LI> CSN5 enzyme activity controls T cell suppression via PD-L1 deubiquitination </LI> <LI> Destabilization of PD-L1 by CSN5 inhibitor curcumin benefits anti-CTLA4 therapy </LI> </UL> </P> <P><B>Graphical Abstract</B></P> <P>[DISPLAY OMISSION]</P>
Leptomycin B Increases Radiosensitization by Trichostain A in HeLa Cells
In Ah Kim(김인아),Jin Ho Kim(김진호),Jin Hee Shin(신진희),Il Han Kim(김일한),Jae Sung Kim(김재성),Hong Gyun Wu(우홍균),Eui Kyu Chie(지의규),Yong Ho Kim(김용호),Bo Kyung Kim(김보경),Semie Hong(홍세미),Sung Whan Ha(하성환),Chan Il Park 대한방사선종양학회 2005 Radiation Oncology Journal Vol.23 No.2
목 적: 히스톤탈아세틸화효소 억제제는 그 자체의 항암효과뿐만 아니라 방사선 감작제로서의 효과가 점차 분명해져가고 있다. 최근 Class I 특이적인 히스톤탈아세틸화효소 억제제의 개발로 계층 특이적인(class specific) 연구가 가능해짐에 따라, 본 연구에서는 서로 다른 히스톤탈아세틸화효소억제제의 방사선감작효과를 비교함과 동시에 p53 발현도의 차이가 히스톤탈아세틸화효소억제제의 방사선 감수성에 미치는 영향을 알아보고자 하였다. 대상 및 방법: 이를 위해 p53 발현도가 매우 낮은 HeLa 세포에 p53의 핵 외 수송을 억제하여 세포질 내 분해를 차단하는 Leptomycin B를 처리하여 p53의 발현도를 현저하게 높인 후, Trichostatin와 SK7041의 방사선 민감도를 비교 관찰하였다. 결 과: 세포생존곡선, SER 및 SF2를 비교 분석 시, p53의 발현이 높은 Leptomycin B 처리군에서 TrichostatinA가 Class I HDAC만을 억제하는 SK7041에 비해 유의하게 높은 방사선 감작효과를 나타내었다. 이는 p53이 Class I 특이적 억제제인 SK7041과 Class I과 II를 모두 억제하는 TSA의 방사선감작효과에 미치는 영향의 차이에 기전적으로 관여함을 시사한다. 결 론: Leptomycin B에 의해 유도된 p53의 발현증가는 Class I과 Class I과 II를 모두 억제하는 TSA의 방사선 감작효과를 증강시킨다. Purpose: Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components of anticancer therapy and their radiosensitizing effects have become evident. Specific HDIs are now available that preferentially inhibit specific HDAC classes; TSA inhibits Class I and II HDACs, and SK7041 inhibits Class I HDACs. Materials and Methods: We tested the differential radiosensitization induced by two different classes of HDIs in HeLa cells. We next tested the hypothesis that p53 expression in cancer cells may influence the susceptibility to HDIs by using pharmacologic modification of the p53 status under an isogenic background. Results: It is interesting that p53 expression in the HeLa cells clearly increased the degree of radiosensitization by TSA compared to that of the class I specific inhibitor SK7041. This suggests that p53 may, in part, be responsible for the mechanistic role for the greater radiosensitization induced by Class I & II inhibitors compared to that of the class I specific inhibitors. Thus, these studies are useful in distinguishing between events mediated solely by the Class I HDACs versus those events involving the other classes of HDACs as well. Conclusion: The anticancer efficacy of targeting Class I and II HDACs, in conjunction with radiation therapy, may be further enhanced by the restoration of p53 expression.